Cargando…

Irinotecan‐induced severe hypotension in a patient with lung cancer

Most hypotension during chemotherapy is caused by an allergic mechanism. Conversely, non‐allergic hypotension due to chemotherapy is rare. In this case report, we present a patient who suffered severe hypotension followed by the administration of irinotecan‐based chemotherapy and some supportive car...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Ryota, Momo, Kenji, Matsuzaki, Airi, Sakai, Akiko, Uchikura, Takeshi, Tanaka, Katsumi, Numazawa, Satoshi, Sasaki, Tadanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021929/
https://www.ncbi.nlm.nih.gov/pubmed/35474996
http://dx.doi.org/10.1002/ccr3.5718
_version_ 1784689958355730432
author Nakano, Ryota
Momo, Kenji
Matsuzaki, Airi
Sakai, Akiko
Uchikura, Takeshi
Tanaka, Katsumi
Numazawa, Satoshi
Sasaki, Tadanori
author_facet Nakano, Ryota
Momo, Kenji
Matsuzaki, Airi
Sakai, Akiko
Uchikura, Takeshi
Tanaka, Katsumi
Numazawa, Satoshi
Sasaki, Tadanori
author_sort Nakano, Ryota
collection PubMed
description Most hypotension during chemotherapy is caused by an allergic mechanism. Conversely, non‐allergic hypotension due to chemotherapy is rare. In this case report, we present a patient who suffered severe hypotension followed by the administration of irinotecan‐based chemotherapy and some supportive care such as steroids for preventing emesis. A 71‐year‐old man with hypertension was diagnosed with stage IV small cell lung cancer (sT1cN3M0). Severe hypotension occurred in the patient after every administration of chemotherapy. Finally, he was able to receive all four courses of chemotherapy as planned along with the medical staff’s support care. This case provides that a regimen that contained irinotecan and steroid could cause hypotension and the mechanism is partially explained by inhibiting choline esterase and adrenal insufficiency. We should be careful about non‐allergic hypotension when we administer irinotecan‐based chemotherapy.
format Online
Article
Text
id pubmed-9021929
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90219292022-04-25 Irinotecan‐induced severe hypotension in a patient with lung cancer Nakano, Ryota Momo, Kenji Matsuzaki, Airi Sakai, Akiko Uchikura, Takeshi Tanaka, Katsumi Numazawa, Satoshi Sasaki, Tadanori Clin Case Rep Case Reports Most hypotension during chemotherapy is caused by an allergic mechanism. Conversely, non‐allergic hypotension due to chemotherapy is rare. In this case report, we present a patient who suffered severe hypotension followed by the administration of irinotecan‐based chemotherapy and some supportive care such as steroids for preventing emesis. A 71‐year‐old man with hypertension was diagnosed with stage IV small cell lung cancer (sT1cN3M0). Severe hypotension occurred in the patient after every administration of chemotherapy. Finally, he was able to receive all four courses of chemotherapy as planned along with the medical staff’s support care. This case provides that a regimen that contained irinotecan and steroid could cause hypotension and the mechanism is partially explained by inhibiting choline esterase and adrenal insufficiency. We should be careful about non‐allergic hypotension when we administer irinotecan‐based chemotherapy. John Wiley and Sons Inc. 2022-04-21 /pmc/articles/PMC9021929/ /pubmed/35474996 http://dx.doi.org/10.1002/ccr3.5718 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Nakano, Ryota
Momo, Kenji
Matsuzaki, Airi
Sakai, Akiko
Uchikura, Takeshi
Tanaka, Katsumi
Numazawa, Satoshi
Sasaki, Tadanori
Irinotecan‐induced severe hypotension in a patient with lung cancer
title Irinotecan‐induced severe hypotension in a patient with lung cancer
title_full Irinotecan‐induced severe hypotension in a patient with lung cancer
title_fullStr Irinotecan‐induced severe hypotension in a patient with lung cancer
title_full_unstemmed Irinotecan‐induced severe hypotension in a patient with lung cancer
title_short Irinotecan‐induced severe hypotension in a patient with lung cancer
title_sort irinotecan‐induced severe hypotension in a patient with lung cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021929/
https://www.ncbi.nlm.nih.gov/pubmed/35474996
http://dx.doi.org/10.1002/ccr3.5718
work_keys_str_mv AT nakanoryota irinotecaninducedseverehypotensioninapatientwithlungcancer
AT momokenji irinotecaninducedseverehypotensioninapatientwithlungcancer
AT matsuzakiairi irinotecaninducedseverehypotensioninapatientwithlungcancer
AT sakaiakiko irinotecaninducedseverehypotensioninapatientwithlungcancer
AT uchikuratakeshi irinotecaninducedseverehypotensioninapatientwithlungcancer
AT tanakakatsumi irinotecaninducedseverehypotensioninapatientwithlungcancer
AT numazawasatoshi irinotecaninducedseverehypotensioninapatientwithlungcancer
AT sasakitadanori irinotecaninducedseverehypotensioninapatientwithlungcancer